- Home
- CELC vs LBTYB Comparison
CELC vs LBTYB Comparison
Compare CELC & LBTYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELC | LBTYB |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | Bermuda |
| Employees | N/A | 6636 |
| Industry | Medical Specialities | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 4.4B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CELC | LBTYB |
|---|---|---|
| Price | $114.28 | $12.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $106.63 | N/A |
| AVG Volume (30 Days) | ★ 527.9K | 8.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $15.41 |
| Revenue Next Year | N/A | $2.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.58 | $9.20 |
| 52 Week High | $120.32 | $29.01 |
Technical Indicators
Market Signals| Indicator | CELC | LBTYB |
|---|---|---|
| Relative Strength Index (RSI) | 56.01 | 46.56 |
| Support Level | $97.75 | $10.28 |
| Resistance Level | $114.54 | $13.03 |
| Average True Range (ATR) | 5.14 | 0.60 |
| MACD | 0.36 | -0.16 |
| Stochastic Oscillator | 63.53 | 18.36 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About LBTYB Liberty Global Ltd. Class B
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.